104 results on '"Le Rhun, Émilie'
Search Results
2. Translating the theranostic concept to neuro-oncology: disrupting barriers
3. “Symptomatic” melanoma brain metastases: A call for clear definitions and adoption of standardized tools
4. Real-time glioblastoma tumor microenvironment assessment by SpiderMass for improved patient management
5. Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial
6. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group
7. Pharmacotherapy for leptomeningeal disease in breast cancer
8. A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups
9. Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)
10. Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101
11. Spatial analysis of the glioblastoma proteome reveals specific molecular signatures and markers of survival
12. Spatial analysis of the glioblastoma proteome reveals specific molecular signatures and markers of survival
13. Tumors: Brain
14. CNS Tumors in Older Adults
15. Treatment of Leptomeningeal Metastases
16. Clinical, Imaging, and CSF Cytological Presentation of Leptomeningeal Metastases from Solid Non-CNS Primary Tumors
17. Hydrocephalus Related to CNS Malignancies in Adults
18. Brain Metastases and Leptomeningeal Metastases
19. The Role of a Proprotein Convertase Inhibitor in Reactivation of Tumor-Associated Macrophages and Inhibition of Glioma Growth
20. Sex-specific aspects of epidemiology, molecular genetics and outcome: primary brain tumours
21. Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma
22. Ethanol Exposure During the Intravenous Administration of Chemotherapeutic Drugs: An Analysis of Clinical Practice and a Literature Review
23. Neurological Complications of Breast Cancer and Its Treatment
24. Leptomeningeal Metastasis as Complication of Systemic Cancers
25. Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases
26. How we treat glioblastoma
27. How we treat patients with leptomeningeal metastases
28. Corrigendum to “Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial” [Eur J Cancer 198 (2024) 113475]
29. Associations of anticoagulant use with outcome in newly diagnosed glioblastoma
30. Diagnostic value of 18F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site
31. Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis
32. The Evolving Landscape of Brain Metastasis
33. Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer
34. 3088: Association of brain metastases with classification, treatment, and outcomes of extracranial OMD
35. Evaluation of non-supervised MALDI mass spectrometry imaging combined with microproteomics for glioma grade III classification
36. European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma
37. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
38. Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults
39. Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
40. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection
41. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial
42. Response to “Intrathecal trastuzumab: What else do we need to consider?” by Gao et al.
43. Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis
44. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
45. Spatial analysis of the glioblastoma proteome reveals specific molecular signatures and markers of survival
46. Liquid biopsy in gliomas: a RANO review and proposals for clinical applications
47. Ethanol Exposure During the Intravenous Administration of Chemotherapeutic Drugs: An Analysis of Clinical Practice and a Literature Review
48. Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis.
49. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
50. Glioblastoma quo vadis: Will migration and invasiveness reemerge as therapeutic targets?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.